Skip to Content

Afrezza (insulin inhalation, rapid acting) Disease Interactions

There are 6 disease interactions with Afrezza (insulin inhalation, rapid acting):

Major

Inhaled Insulin (Includes Afrezza) ↔ Acute Bronchospasm

Severe Potential Hazard, Moderate plausibility

Applies to: Chronic Obstructive Pulmonary Disease, Asthma

The use of inhaled insulin is contraindicated in patients with chronic lung disease such as asthma and COPD. Acute bronchospasm has been observed after an inhaled insulin dosage. Prior to initiating therapy with an inhaled insulin product, it is recommended to evaluate all patients medical history, physical examination and spirometry (FEV1) to identify potential underlying lung disease.

Moderate

Inhaled Insulin (Includes Afrezza) ↔ Diabetic Ketoacidosis

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetic Ketoacidosis, Diabetes Type 1, Infection - Bacterial/Fungal/Protozoal/Viral

Rapid acting inhaled insulin may predispose certain patients to develop diabetic ketoacidosis (DKA). In clinical trials, subjects with type 1 diabetes receiving inhaled insulin were more likely to develop DKA than patients receiving comparator agents. It is recommended to increase the frequency of glucose monitoring and to consider using an alternate route of administration, if appropriate, in patients at risk for DKA, such as patients with an acute illness or infections.

Moderate

Inhaled Insulin (Includes Afrezza) ↔ Lung Cancer

Moderate Potential Hazard, Moderate plausibility

Applies to: Lung Cancer

In clinical trials, lung cancer was observed in smoker and non-smoker patients using inhaled insulin. In patients with active lung cancer, a prior history of lung cancer, or in patients at risk for lung cancer, it is recommended to consider whether the benefits of inhaled insulin use outweigh this potential risk.

Moderate

Insulin (Includes Afrezza) ↔ Renal/Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease, Renal Dysfunction

Insulin requirements may be diminished in patients with renal or hepatic impairment due to reduced insulin metabolism and, in the latter case, also to reduced capacity for gluconeogenesis. Lower initial dosages may be appropriate, with careful monitoring of plasma glucose levels and dosing adjustments.

References

  1. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  2. "Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.
  3. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
Moderate

Insulin- Hypokalemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hypokalemia

Hypokalemia may commonly occur during treatment with insulin. Use with caution in patients who may be particularly at risk of developing hypokalemia (e.g., patients using potassium-lowering medications, patients taking medications sensitive to serum potassium concentrations).

Moderate

Insulin/Oral Hypoglycemic Agents (Includes Afrezza) ↔ Hypoglycemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Adrenal Insufficiency, Malnourished, Autonomic Neuropathy, Panhypopituitarism, Anorexia/Feeding Problems

Hypoglycemia may commonly occur during treatment with insulin and/or oral hypoglycemic agents. Care should be taken in patients who may be particularly susceptible to the development of hypoglycemic episodes during the use of these drugs, including those who are debilitated or malnourished, those with defective counterregulatory mechanisms (e.g., autonomic neuropathy and adrenal or pituitary insufficiency), and those receiving beta-adrenergic blocking agents.

References

  1. "Product Information. Glucophage (metformin)." Bristol-Myers Squibb, Princeton, NJ.
  2. "Product Information. Novolog (insulin aspart)" Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  3. Fauci AS, Braunwald E, Isselbacher KJ, Wilson JD, Martin JB, Kasper DL, Hauser SL, Longo DL, eds. "Harrison's Principles of Internal Medicine. 14th ed." New York, NY: McGraw-Hill Health Professionals Division (1998):
  4. "Product Information. Glucotrol (glipizide)." Pfizer US Pharmaceuticals, New York, NY.
  5. "Product Information. Prandin (repaglinide)." Novo Nordisk Pharmaceuticals Inc, Princeton, NJ.
  6. "Product Information. Humulin BR (insulin)." Lilly, Eli and Company, Indianapolis, IN.
  7. "Product Information. Lantus (insulin glargine)" Aventis Pharmaceuticals, Swiftwater, PA.
  8. "Product Information. Diabeta (glyburide)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  9. "Product Information. Dymelor (acetohexamide)" Lilly, Eli and Company, Indianapolis, IN.
  10. "Product Information. Amaryl (glimepiride)." Hoechst Marion-Roussel Inc, Kansas City, MO.
  11. "Product Information. Tolinase (tolazamide)" Pharmacia and Upjohn, Kalamazoo, MI.
  12. "Product Information. Micronase (glyburide)." Pharmacia and Upjohn, Kalamazoo, MI.
  13. "Product Information. Starlix (nateglinide)" Novartis Pharmaceuticals, East Hanover, NJ.
  14. "Multum Information Services, Inc. Expert Review Panel"
  15. "Product Information. Diabinese (chlorpropamide)." Pfizer US Pharmaceuticals, New York, NY.
View all 15 references

Afrezza (insulin inhalation, rapid acting) drug Interactions

There are 890 drug interactions with Afrezza (insulin inhalation, rapid acting)

Afrezza (insulin inhalation, rapid acting) alcohol/food Interactions

There is 1 alcohol/food interaction with Afrezza (insulin inhalation, rapid acting)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide